Is BPC-157 Legal? What the 2026 FDA Vote Changed

As of October 2026, owning BPC-157 is not a federal crime, but nearly everything built around it is restricted. It cannot be lawfully prescribed, compounded by a pharmacy or marketed for human use, and it has no approved use in a drug. The table matches each situation to its status.

The sources behind the rows:

• The Drug Enforcement Administration (DEA) publishes the federal controlled-substance schedules. BPC-157 is not among them.
• Operation Supplement Safety (OPSS), the Department of Defense's supplement-safety program, states that BPC-157 "is not a dietary ingredient. It is an unapproved drug and cannot be legally prescribed or sold over the counter" (OPSS, April 29, 2025).
• Products are sold as supplements anyway. FDA's briefing document records that BPC-157 is marketed in the United States as an ingredient in oral capsules and tablets, and that it is not a component of any FDA-approved drug.
• Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) governs patient-specific compounding by state-licensed pharmacies. In practice a pharmacy can compound only from approved ingredients or from substances on FDA's 503A bulks list.
• FDA states that it is illegal for consumers to import unapproved drugs into the U.S.

This page is general information, not legal or medical advice.

No. The July 23, 2026 vote was a recommendation to FDA, not a decision, and as of October 2026 FDA has not added BPC-157 to the 503A bulks list, the step that would let pharmacies compound it. FDA's evaluators proposed that neither BPC-157 (free base) nor BPC-157 acetate be listed (FDA committee slides, July 23, 2026).

The April 2026 change fed the confusion. By April 22, 2026, FDA had moved BPC-157 off its list of substances that may present significant safety risks (Category 2) and into a "nominated but withdrawn" table, after the nominators withdrew their requests (FDA safety-risks page). That did not make BPC-157 permitted. FDA's slides describe the situation as withdrawn nominations, with FDA evaluating the substances at its discretion.

Even a listing would not make BPC-157 an approved drug. FDA's slides state that a compounded product is not FDA-approved, need not carry a label explaining how to use it, and need not follow current good manufacturing practice. Compounders need not report adverse events to FDA. Unless the entry carries limits, a listed substance can be compounded for any use or route.

To check the current position, open FDA's 503A bulks list page and look for BPC-157 among the listed substances. A news story or a clinic's website is not a substitute.

FDA's reviewers found very little human evidence: five published clinical studies in which about 81 people received BPC-157 (our sum of FDA's participant counts). All used rectal, joint, bladder or intravenous (IV) routes. None tested the oral, subcutaneous, nasal or skin routes consumers use (FDA briefing document; committee slides).

Our sum of the participant numbers FDA lists:

24 + 26 + 17 + 12 + 2 = 81. The table counts only people dosed. The colitis trial randomized 53 people, and about 26 of them received BPC-157. FDA gives that figure as approximate, so the total is approximate too.

The one randomized colitis trial gave 80 mg, which is 80,000 micrograms (µg), as an enema. The capsules in the withdrawn nominations ran from 250 µg to 1 mg (1,000 µg). By our arithmetic, the trial dose was 80 times the largest proposed capsule and 320 times the smallest. These are nominal doses by different routes, so this is not an equivalence of effect. It only shows that the capsules were never tested at any trial dose. FDA noted that the trial exists only as a meeting abstract with missing detail. The 95% confidence interval for the difference from placebo (−4.84 to 1.62 points) includes zero.

Other findings:

• Animal safety: 28-day injection studies in rats and dogs showed changes in clotting time and liver-related markers. No longer studies were available.
• Quality gaps: The certificates of analysis FDA examined had no impurity detail, no data on peptide clumping (aggregation), and no bioburden (living microbe count) or bacterial endotoxin results. FDA flagged a significant risk of immune reactions for injected and nasal forms.
• Adverse events: FDA searched its Adverse Event Reporting System (FAERS) through December 4, 2025 and found three reports, all involving injectable BPC-157, one with an emergency room visit. FDA judged one rechallenge reaction likely caused by the product, which also contained TB-500, another peptide. It could not attribute the others because of other drugs or missing information.
• Approval status: FDA's search of the globalEDGE database found no approved product containing BPC-157 in any country, and no monograph exists in the European, Japanese or International Pharmacopeias.

FDA concluded that the balance of its four criteria weighs against listing. Our reading is that the legal question and the evidence question point the same way, which is why a vial's quality is the first practical question for any buyer.

No. FDA judges a product by how it is marketed, not by what the label says. In a June 12, 2023 warning letter to Warrior Labz, FDA wrote that "despite statements on your product labeling marketing your products for 'research purpose only' and 'not for human consumption,' evidence obtained from your website establishes that your products are intended to be drugs for human use."

The letter cited FDCA sections 301(d) and 505(a), which prohibit introducing an unapproved new drug into interstate commerce. It quoted the seller's own claims that BPC-157 protects organs and combats gastric ulcers, leaky gut and Crohn's disease.

FDA's own review shows why the label does not describe reality. One adverse event report it examined involved a patient who injected a BPC-157 and TB-500 product labeled for "research purposes only" twice daily for joint and wound healing.

In our judgement, the signals to watch are dosing guides, injection supplies and benefit claims sitting beside a research-only disclaimer. Each one is evidence of human-use intent.

Run each claim, from a clinic, a vendor or an article, through six tests with a clear pass or fail. These are our recommended tests, built from the FDA findings above.

No. BPC-157 is prohibited under the S0 category (non-approved substances) of the World Anti-Doping Agency (WADA) list. The U.S. Anti-Doping Agency (USADA) states that it "is not approved for human clinical use by the U.S. Food and Drug Administration (FDA) or any other global health authority" (USADA). The Department of Defense also places it on its prohibited dietary supplement ingredients list under Department of Defense Instruction 6130.06 (OPSS).

As of October 2026, BPC-157 has no approved use in a U.S. human drug, so a U.S. buyer must confirm the lawful end use (for example non-clinical research) and the import requirements with a regulatory adviser before ordering. We supply BPC-157 as a bulk active pharmaceutical ingredient (API) in raw powder form, not finished vials, to qualified business buyers: generic manufacturers, contract formulators, distributors, importers and research laboratories. Our supply is for export and institutional use, not for individuals.

We do not claim Drug Master File (DMF), Certificate of Pharmaceutical Product (CPP) or Certificate of Suitability (CEP) support, or other U.S. regulatory filings, for our APIs. Regulatory status and permitted end use are decided per product and destination. We do not represent research-only material as an approved human pharmaceutical API.

This is how we handle a request:

We quote product by product, so ask us for pricing. FDA's quality findings are the specification list to bring to any supplier, including us. For the checks that matter before a purchase order, see our guide to peptide API supply chain qualification. To request a BPC-157 quotation, email sunil@aarisepharma.com, message +91 9899783330 on WhatsApp, or contact us through our website.